As 2024 comes to a close, we would like to celebrate the advancements made in small cell lung cancer (#SCLC) that provide hope. This tremendous progress by clinical trials reflects the innumerable sacrifices made by such dedicated patients & their wonderful families. Thank you!

What is the biology of small cell lung cancer? What are the neuroendocrine subtypes? Can we use therapies to target the NE subtypes? @lungevity #SCLC #meded #lcsm @SclcSMASHERS @SCLCYIForum @SWOG @Annechiangmd

No real progress was made in small cell lung cancer for almost four decades. Recent studies with new agents brought hope. Deciding what therapy for which patients still remains a challenge. Treatment options for #SCLC after progression are limited. In @TheShieldsLab at

Just published: These findings provide insights into the molecular heterogeneity of small-cell lung cancer and highlight potential biomarkers for targeted therapies. https://t.co/cCuNuMVx3P @teekayowo @GlopesMd @OncoAlert @SclcSMASHERS #SCLC #LCSM

@drshieldsmd @ASCO @IUCancerCenter @centergrove_mag @TheShieldsLab @SclcSMASHERS @SCLCYIForum Beautiful!! 👏🏻👏🏻👏🏻

Beyond proud 🥹 of my trainee Anthony Cuadros on his recent commentary, “One More Lap.” This article was written from the heart with our personal experiences and his unique viewpoints as a young investigator in #SCLC, now published in @ASCO Connections. We detail the lessons

Looking forward to our NEXT @SclcSMASHERS Fireside Chat this Friday 2/6 at 12p EST on YouTube! My good friend (co-residents at @VUMChealth) and world renown thoracic oncology expert Dr. Eric Singhi (@lungoncdoc) from @MDAndersonNews will be our guest! We will discuss the

Join us for a YouTube Live on 2/6, with @lungoncdoc (@MDAndersonNews) as we discuss the role of community and support in people with small cell lung cancer. Tune in: https://t.co/GMXNK8xTWm @sclcsmashers @drshieldsmd @TheShieldsLab #sclc #lungcancer

🫁 New paper in ESMO Open from the #NYLCFSummit2025! https://t.co/sFOzlqnWAc @fred_hirsch @peters_solange @JairBar4 @RajaFlores @NarjustFlorezMD @FordePatrick @thelouisgros @BalazsHalmosMD @dplanchard @ReckampK @triparnasen @drshieldsmd @SclcSMASHERS

Thank you to moderators Ann Steagall RN @nursesteagall and Dr. Upal Roy @LUNGevity for a lovely discussion. In our latest @SclcSMASHERS Fireside Chat, we highlighted @TheShieldsLab research, including recent biomarker discoveries for response to lurbinectedin, active liquid

As we wrap up 2025, there is an overwhelming gratefulness in my heart ❤️ for the unprecedented advancements 🧬 in treatments 💊 & research 🔬 for #SCLC! Options that improved the care and lives of patients and their loved ones impacted by #SCLC! Thank you to ALL of the

NOW ON YOUTUBE! Join the @SCLCSmashers conversation on January 9 w/ @drshieldsmd (@theshieldslab) moderated by @lungevity's Dr. Upal Basu Roy and Ann Fish-Steagall. Tune in by visiting https://t.co/TGnbPZgZlE #lcsm #smallcell #lungcancer

Join us on 11/25 for a Facebook Live w/ Dr. Trudy Oliver (@DukeMedSchool) to discuss the origins of #smallcell #lungcancer and its impact on plasticity. Moderated by @drshieldsmd (@IUHealth @SCLCSMASHERS) Ann Fish-Steagall (@lungevity). Tune in by visiting https://t.co/UMN7nNl2O9

Our 2nd #keynote speaker, Dr. Greg Kalemkerian from University of Michigan delivers an overview of the current and historic landscape of the treatment of #SCLC @SclcSMASHERS #LCSM #Oncology

Thank you @ConquerCancerFd for highlighting how important it is to change the stigma, nihilism, and culture surrounding a diagnosis of lung cancer. Anyone with lungs 🫁 can be diagnosed with lung cancer, and no one deserves lung cancer. Patients with #SCLC deserve MORE

Unfortunately, while DLL3 is widely expressed (93%+) in tumors post-SCLC transformation ( https://t.co/ySAC2zeX7g), it is not clearly an actionable or biologically relevant target for transformed SCLC. This is similar to EGFR alterations and anti-PD-1/PD-L1 therapies, despite high

A true giant in the field of small cell lung cancer! An absolute honor to have Dr. Anish Thomas (@NIH) as a visiting professor at @IUCancerCenter, presenting his groundbreaking research with a “reverse translational” approach (patient bedside to the bench, and back!) on #SCLC.

This morning’s DeLLphi presentation @myESMO brings so much hope to our #lungcancer community. Love seeing fresh hope for those with small cell lung cancer. #ESMO25

Tarlatamab incorporated upfront with chemo-immunotherapy breaks all the known stats in first-line SCLC. No new data safety concerns. Awaiting data from randomized ph3 trial, but likely to be the next SoC. #ESMO25 #SCLC @SclcSMASHERS

🔥Off the press: #IDeate-Lung01 IDxD Ifinatamab Deruxtecan (B7 H3 ADC) in Patients With Extensive-Stage SCLC: ▶️ Phase 2 N=183 ORR 48.2%, mPFS 4.9 mos ▶️Any TRAEs 89%, ILD 12% ▶️ Phase3 ongoing @SclcSMASHERS | Journal of Clinical Oncology

A lifelong dream came true today. Almost exactly 25 years ago today, I lost my strong Marine father to small cell lung cancer. Lost and broken into a million pieces, I sought out Dr. John Minna as a teenager to learn how I could become a translational thoracic oncologist to